A new peer-reviewed, in vitro study using the gold-standard INFOGEST digestion model has been published, demonstrating that Pepzyme AG, a proteolytic enzyme blend from Specialty Enzymes & Probiotics, promotes enhanced collagen breakdown and increased release of low-molecular-weight bioactive peptides.
The research, which used the gold-standard INFOGEST digestion model, suggests that the ingredient can help consumers utilise the collagen they consume.
This result is especially important for consumers taking GLP-1 medications, who need support for collagen digestion and metabolic function.
Furthermore, the released peptides demonstrate more than 30% improvement in anti-diabetic (DPP-IV inhibitory) activity, supporting the body's natural GLP-1 activity and complementing GLP-1 therapies.
This transforms collagen into a functional ingredient that supports both the metabolic and structural challenges facing GLP-1 users—from impaired protein digestion to accelerated lean muscle and bone loss.
"Pepzyme AG gives brands the scientific foundation to position collagen as essential GLP-1 support, not just a protein supplement," said Reshma Rathi, Vice President of Specialty Enzymes & Probiotics.
"It's a straightforward formulation upgrade that supports premium positioning in the fastest-growing segment of metabolic health."
Why this matters
GLP-1 use is projected to reach 30 million Americans by 2030.
Integrating an ingredient such as Pepzyme AG that helps GLP-1 users in digesting collagen and that complements GLP-1therapies will give collagen brands vital differentiation in a market where science drives success.